IL1B and type 2 diabetes mellitus: While the results of ex vivo and clinical studies on the role of IL-1β in T2DM are promising, some questions still remain to be answered including the precise mechanism of action of in vivo IL-1 inhibition, possible longer term outcomes with such a therapy, and the therapeutic potential of IL-1β inhibitors vs. other symptomatic therapies.